Published in PLoS One on May 31, 2012
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (2013) 5.78
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev (2014) 5.14
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med (2012) 2.54
What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One (2013) 2.05
Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med (2016) 1.81
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One (2013) 1.71
Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol (2013) 1.66
A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. PLoS One (2015) 1.60
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. Int J Tuberc Lung Dis (2014) 1.59
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health (2012) 1.57
Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis (2015) 1.56
Point-of-care laboratory of pathogen diagnosis in rural Senegal. PLoS Negl Trop Dis (2013) 1.44
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis (2013) 1.39
Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS One (2015) 1.35
State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control. PLoS One (2013) 1.16
Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis (2013) 1.15
The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study. PLoS One (2012) 1.11
Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS One (2013) 1.05
Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. J Clin Microbiol (2014) 1.04
Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis (2014) 1.02
Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. Clin Infect Dis (2013) 0.89
Incremental value of T-SPOT.TB for diagnosis of active pulmonary tuberculosis in children in a high-burden setting: a multivariable analysis. Thorax (2013) 0.89
Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income Countries. Health Econ (2016) 0.87
Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations. PLoS One (2014) 0.87
Health-care workers' perspectives on workplace safety, infection control, and drug-resistant tuberculosis in a high-burden HIV setting. J Public Health Policy (2013) 0.85
Using Xpert MTB/RIF. Curr Respir Med Rev (2013) 0.83
Reasons for the low bacteriological coverage of tuberculosis reported in Mpumalanga Province, South Africa. Public Health Action (2015) 0.81
Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making. Int J Infect Dis (2015) 0.81
Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costs. Sci Rep (2015) 0.81
Cost-effectiveness thresholds: pros and cons. Bull World Health Organ (2016) 0.81
Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study. BMC Infect Dis (2017) 0.80
Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. PLoS One (2016) 0.80
Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Int J Tuberc Lung Dis (2016) 0.79
Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens. J Clin Microbiol (2016) 0.78
Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. Int J Tuberc Lung Dis (2014) 0.78
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One (2016) 0.78
Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness. Int J Tuberc Lung Dis (2016) 0.77
Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design. PLoS One (2016) 0.77
Infectious Diseases (ID) Learning Unit: How Rapidly to Evaluate for Active Tuberculosis Disease in Low-Prevalence Settings. Open Forum Infect Dis (2016) 0.75
Promoting development and uptake of health innovations: The Nose to Tail Tool. F1000Res (2016) 0.75
Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo. BMC Res Notes (2015) 0.75
Cost analysis of nucleic acid amplification for diagnosing pulmonary tuberculosis, within the context of the Brazilian Unified Health Care System. J Bras Pneumol (2015) 0.75
The Use of Xpert MTB/Rif for Active Case Finding among TB Contacts in North West Province, South Africa. Tuberc Res Treat (2016) 0.75
Translating genomics research into control of tuberculosis: lessons learned and future prospects. Genome Biol (2014) 0.75
Evaluation of the implementation of the Xpert® MTB/RIF assay in Fiji. Public Health Action (2014) 0.75
The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. Bull World Health Organ (2017) 0.75
Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med (2010) 32.89
Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet (2007) 9.71
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev (2011) 3.63
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med (2011) 2.76
Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis (2010) 2.59
Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med (2011) 2.24
Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. Int J Tuberc Lung Dis (2003) 2.19
Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis (2008) 2.04
TB diagnostic tests: how do we figure out their costs? Expert Rev Anti Infect Ther (2009) 1.47
The role of health economics research in implementation research for health systems strengthening. Int J Tuberc Lung Dis (2011) 0.99
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health (2010) 8.81
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health (2010) 3.79
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA (2008) 3.78
Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health (2010) 3.34
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health (2008) 3.16
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS (2009) 2.97
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health (2004) 2.76
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med (2011) 2.76
Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ (2010) 2.68
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn (2010) 2.47
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008-2013. J Acquir Immune Defic Syndr (2015) 2.44
Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. J Acquir Immune Defic Syndr (2012) 2.41
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS (2005) 2.24
Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med (2011) 2.23
Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health (2010) 2.19
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol (2012) 2.19
Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care (2009) 2.11
Prevalence of HIV infection and median CD4 counts among health care workers in South Africa. S Afr Med J (2007) 2.09
Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health (2010) 2.05
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS (2010) 1.92
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis (2006) 1.87
Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol (2009) 1.87
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 1.86
Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr (2012) 1.78
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J (2007) 1.77
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2013) 1.77
Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat (2010) 1.75
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One (2013) 1.71
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med (2005) 1.67
How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS One (2012) 1.66
Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther (2009) 1.66
A community-based study to examine the effect of a youth HIV prevention intervention on young people aged 15-24 in South Africa: results of the baseline survey. Trop Med Int Health (2005) 1.65
Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Organ (2012) 1.64
Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS (2008) 1.63
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr (2008) 1.62
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health (2013) 1.58
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J (2012) 1.58
Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health (2012) 1.57
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS (2009) 1.56
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med (2014) 1.51
Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom (2008) 1.50
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa. Lancet (2005) 1.45
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc (2010) 1.45
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis (2006) 1.44
Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One (2010) 1.42
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr (2011) 1.42
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis (2003) 1.41
Outpatient treatment of children with severe pneumonia with oral amoxicillin in four countries: the MASS study. Trop Med Int Health (2011) 1.41
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health (2014) 1.38
Defining retention and attrition in pre-antiretroviral HIV care: proposals based on experience in Africa. Trop Med Int Health (2012) 1.37
Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerg Infect Dis (2011) 1.36
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis (2011) 1.33